Overactive growth controller could become drug target Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment. Reporting in the January issue of Cancer Cell, a team led by Qunyan Yu, MD, and Peter Sicinski, MD, PhD, of Dana-Farber say that the interaction of a certain mutated oncogene and the newly described growth control flaw is seen in about 10 percent of breast cancers - and the deadliest ones. The cancer results from a cascade of molecular events. The...